| ExTRACT-TIMI 25 trial: clarifying the role of enoxaparin in patients with ST-elevation myocardial infarction receiving fibrinolysis. | |
| | |
MedLine Citation:
|
PMID: 17867915 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Pharmacologic reperfusion remains the most common treatment strategy for ST-elevation myocardial infarction (STEMI) worldwide. Unfractionated heparin (UFH) is the established adjunctive antithrombotic agent used with fibrinolytic agents. Low-molecular-weight heparins (LMWHs) are a potential alternative to UFH, but have not been evaluated in large cohorts of patients. The Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment (ExTRACT)-Thrombolysis in Myocardial Infarction (TIMI) 25 was a double-blind, double-dummy randomized controlled trial, of 20,479 patients, which demonstrated the superiority of enoxaparin over UFH in reducing death or nonfatal myocardial infarction (MI) at 30 days, with an increase in major bleeding. The composite of death, nonfatal MI and nonfatal intracranial hemorrhage, was reduced with enoxaparin. Elderly patients (> or = 75 years of age) received a novel enoxaparin dosing regimen and when compared with UFH, benefited from a lower relative bleeding risk than younger patients without compromising efficacy in preventing death or MI. Intracranial hemorrhage rates were similar. The net clinical benefit of enoxaparin over UFH was maintained regardless of whether patients were on clopidogrel or not, or whether percutaneous coronary intervention was performed. Enoxaparin is an appropriate choice for adjunctive therapy with fibrinolysis in patients with STEMI. |
| | |
Authors:
|
Ruvin S Gabriel; Harvey D White |
Related Documents
:
|
18340145 - Risk stratification and the management of non-st-segment elevation acute coronary syndr... 19101225 - Temporal course of pregnancy-associated plasma protein-a in angioplasty-treated st-elev... 9851955 - Effect of glycoprotein iib/iiia receptor blockade on recovery of coronary flow and left... 9737475 - Rationale for the management of coronary syndromes with low-molecular-weight heparins. 15972025 - Center of volume and total heart volume variation in healthy subjects and patients befo... 16028325 - Hyperdense pericardial effusion in dermatomyositis and contrast induced nephropathy. |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Expert review of cardiovascular therapy Volume: 5 ISSN: 1744-8344 ISO Abbreviation: Expert Rev Cardiovasc Ther Publication Date: 2007 Sep |
Date Detail:
|
Created Date: 2007-09-17 Completed Date: 2008-04-04 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101182328 Medline TA: Expert Rev Cardiovasc Ther Country: England |
Other Details:
|
Languages: eng Pagination: 851-7 Citation Subset: IM |
Affiliation:
|
Green Lane Cardiovascular Service, Auckland City Hospital, Level 3, Building 32, Private Bag 92 024, Auckland 1030, New Zealand. ruving@adhb.govt.nz |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Age Factors Aged Double-Blind Method Enoxaparin / adverse effects, pharmacology, therapeutic use* Female Fibrinolytic Agents / adverse effects, pharmacology, therapeutic use* Heart Conduction System / drug effects*, physiopathology Heparin, Low-Molecular-Weight / pharmacology, therapeutic use Humans Male Middle Aged Myocardial Infarction / drug therapy*, physiopathology Myocardial Reperfusion / methods* Platelet Aggregation Inhibitors / therapeutic use Risk Factors Survival Analysis Thrombolytic Therapy* Ticlopidine / analogs & derivatives, therapeutic use Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Enoxaparin; 0/Fibrinolytic Agents; 0/Heparin, Low-Molecular-Weight; 0/Platelet Aggregation Inhibitors; 55142-85-3/Ticlopidine; 90055-48-4/clopidogrel |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Aliskiren, the future of renin-angiotensin system blockade?
Next Document: Pregnancy and adult congenital heart disease.